UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of May 2020
COMMISSION
FILE Number.
000-29338
CORREVIO
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
CORREVIO
PHARMA CORP. |
|
(Registrant) |
|
|
|
Date: May 21, 2020 |
By: |
/s/
Justin Renz |
|
|
Name: Justin Renz |
|
|
Title: President and Chief Financial
Officer |
Exhibit 99.1
Correvio Obtains Final Order for Plan
of Arrangement
NASDAQ: CORV TSX: CORV
VANCOUVER, May 21, 2020 /CNW/ - Correvio Pharma
Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company
focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme Court of British
Columbia approving the previously announced plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited
("ADVANZ PHARMA") pursuant to which ADVANZ PHARMA, through its wholly-owned subsidiary Mercury Pharma Group Limited
("Mercury"), has agreed to acquire all of the issued and outstanding shares of Correvio for a total purchase price
of approximately US$76 million, which includes the repayment of certain Correvio indebtedness, as described in Correvio's information
circular dated April 16, 2020.
The Arrangement was previously approved by
Correvio securityholders at the annual general and special meeting of securityholders held on May 15, 2020.
It is currently anticipated that the transaction
will close on May 27, 2020, subject to the satisfaction and/or waiver of all conditions precedent set forth in the arrangement
agreement among Correvio, ADVANZ PHARMA and Mercury. It is expected that the Correvio common shares will be delisted from trading
on the NASDAQ Capital Market and Toronto Stock Exchange shortly after the closing date of the Arrangement.
Further details regarding the Arrangement are
set out in the management information circular which is available under the profile of Correvio at www.sedar.com.
About ADVANZ PHARMA
ADVANZ PHARMA operates an international specialty
pharmaceutical business with a diversified portfolio of more than 200 branded and unbranded products, and sales in more than 90
countries, and going forward, is focused on becoming the leading platform for niche established medicines, with advanced commercial
capabilities throughout Western Europe.
ADVANZ PHARMA's registered office is in Jersey, Channel
Islands. The Company operates globally from its headquarters in London, England and through its subsidiaries in Dublin,
Ireland; Sydney, Australia; Helsingborg, Sweden; Chicago, United States; and Mumbai, India.
About Correvio Pharma Corp.
Correvio Pharma Corp. is a specialty pharmaceutical
company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a
commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes
brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™
(dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio®
(ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP,
HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute
coronary syndrome. Correvio's pipeline of product candidates includes Trevyent®, a drug device combination that
is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.
Correvio is traded on the NASDAQ Capital Market
(CORV) and the Toronto Stock Exchange (CORV). For more information, please visit our web site www.correvio.com.
Correvio's Forward-Looking Statement Disclaimer
Certain statements in this news release contain
"forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking
information" under applicable Canadian securities legislation (collectively, "forward-looking statements").
Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future
revenue or performance, capital expenditures, financing needs and other information that may not be based on historical fact. Forward-looking
statements can often be identified by the use of terminology such as "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect", "look forward
to" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us based
on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors
we believe are appropriate.
By their very nature, forward-looking statements
involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, achievements,
events or developments to be materially different from any future results, performance, achievements, events or developments expressed
or implied by such forward-looking statements. These forward-looking statements include but are not limited to the timing for completion
of the Arrangement, the consideration to be received by securityholders of Correvio, the satisfaction of certain closing conditions
contained in the arrangement agreement and the timing of the delisting of Correvio's common shares from NASDAQ Capital Market and
the Toronto Stock Exchange.
In respect of the forward-looking statements
and information concerning the anticipated completion of the Arrangement and the anticipated timing for completion of the Arrangement,
Correvio has provided them in reliance on certain assumptions and believes that they are reasonable at this time, including the
assumption as to the ability of the parties to satisfy, in a timely manner, the conditions to the closing of the Arrangement. These
dates may change for a number of reasons, including the need for additional time to satisfy the conditions to the completion of
the Arrangement. Accordingly, you should not place undue reliance on the forward-looking statements and information contained in
this new release concerning these times.
These statements reflect Correvio's current
views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered
reasonable by Correvio, are inherently subject to significant business, economic, competitive, political and social uncertainties
and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially
different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements
or information and Correvio has made assumptions and estimates based on or related to many of these factors. Such factors include,
without limitation: risks associated with the arrangement and acquisitions generally, such as the failure to satisfy
the closing conditions contained in the arrangement agreement, the occurrence of a material adverse effect or other events which
may give the parties a basis on which to terminate the arrangement agreement and the risks and uncertainties facing Correvio as
discussed in the annual report and detailed from time to time in our other filings with the Securities and Exchange Commission
("SEC") available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. In particular,
we direct your attention to Correvio's Annual Information Form filed with the Canadian securities regulatory authorities on SEDAR
on March 30, 2020 and Correvio's Annual Report on Form 20-F for the year ended December 31, 2019, filed with the SEC on April 29,
2020. All of the risks and certainties disclosed in those filings are hereby incorporated by reference in their entirety into this
news release.
While Correvio makes these forward-looking
statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking
statements made in this press release. All forward-looking statements made herein are made as of the date hereof based on our current
expectations and we undertake no obligation to revise or update such forward-looking statements to reflect subsequent events, information
or circumstances, except as required by law. Investors are cautioned that forward-looking statements are not guarantees of future
performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to their inherent
uncertainty.
Correvio® and the Correvio Logo
are the proprietary trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International Limited, and used under license.Zevtera®
and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used under license.
Trevyent® is a trademark of SteadyMed Ltd. and used under license.
All other trademarks are the property of their respective owners.
View original content:http://www.prnewswire.com/news-releases/correvio-obtains-final-order-for-plan-of-arrangement-301063882.html
SOURCE Correvio Pharma Corp
View original content: http://www.newswire.ca/en/releases/archive/May2020/21/c6988.html
%CIK: 0001036141
For further information: Justin Renz, President & CFO,
Correvio Pharma Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@correvio.com; Argot Partners, Michelle Carroll/Claudia Styslinger,
212.600.1902, michelle@argotpartners.com, claudia@argotpartners.com
CO: Correvio Pharma Corp
CNW 16:01e 21-MAY-20
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
過去 株価チャート
から 8 2024 まで 9 2024
Correvio Pharma (NASDAQ:CORV)
過去 株価チャート
から 9 2023 まで 9 2024